Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.
van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ, Lamberts SW. van der Hoek J, et al. Among authors: boerlin v. J Clin Endocrinol Metab. 2004 Feb;89(2):638-45. doi: 10.1210/jc.2003-031052. J Clin Endocrinol Metab. 2004. PMID: 14764775 Free article. Clinical Trial.
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jiménez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM. Chanson P, et al. Among authors: boerlin v. Clin Endocrinol (Oxf). 2000 Nov;53(5):577-86. doi: 10.1046/j.1365-2265.2000.01134.x. Clin Endocrinol (Oxf). 2000. PMID: 11106918 Clinical Trial.
The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ, Lamberts SW. van der Hoek J, et al. Among authors: boerlin v. Clin Endocrinol (Oxf). 2005 Aug;63(2):176-84. doi: 10.1111/j.1365-2265.2005.02322.x. Clin Endocrinol (Oxf). 2005. PMID: 16060911 Clinical Trial.
New insights on SOM230, a universal somatostatin receptor ligand.
Boerlin V, van der Hoek J, Beglinger Ch, Poon KW, Hartmann S, Dutreix C, Kovarik JM, Bruns Ch, Weckbecker G, Lewis I, Schnieper P, Hofland LJ, Lamberts SW. Boerlin V, et al. J Endocrinol Invest. 2003;26(8 Suppl):14-6. J Endocrinol Invest. 2003. PMID: 15233205 Clinical Trial. No abstract available.
A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.
Ikeda S, Takano Y, Cynshi O, Tanaka R, Christ AD, Boerlin V, Beyer U, Beck A, Ciorciaro C, Meyer M, Kadowaki T. Ikeda S, et al. Among authors: boerlin v. Diabetes Obes Metab. 2015 Oct;17(10):984-93. doi: 10.1111/dom.12538. Epub 2015 Aug 20. Diabetes Obes Metab. 2015. PMID: 26179482 Clinical Trial.
11 results